BridgeBio Pharma, Inc. Quarterly Deferred Tax Assets, Net of Valuation Allowance in USD from Q4 2018 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
BridgeBio Pharma, Inc. quarterly Deferred Tax Assets, Net of Valuation Allowance history and growth rate from Q4 2018 to Q4 2023.
  • BridgeBio Pharma, Inc. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending December 31, 2023 was $6.47M, a 25.5% increase year-over-year.
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $6.47M +$1.31M +25.5% Dec 31, 2023 10-K 2024-02-22
Q4 2022 $5.16M -$3.1M -37.5% Dec 31, 2022 10-K 2024-02-22
Q4 2021 $8.26M -$27.3M -76.8% Dec 31, 2021 10-K 2023-02-23
Q4 2020 $35.6M +$35.3M +12168% Dec 31, 2020 10-K 2022-02-25
Q4 2019 $290K +$272K +1511% Dec 31, 2019 10-K 2021-02-25
Q4 2018 $18K Dec 31, 2018 10-K 2020-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.